References: 1. ZOMETA^® Summary of Product Characteristics. Novartis Pharma AG. 2. Hoff AO, Toth BB,Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.J Bone Miner Res. 2008;23:826-836. 3. Data on file. Novartis Pharma AG. 4. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaws. http://www.aaoms.org/docs/position_papers/osteonecrosis.pdf. Accessed November 11, 2008. 5. Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. Published online ahead of print, August 2008. 6. Ripamonti CI, Maniezzo M, Campa T, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol. Published online ahead of print, July 2008. 7. Weitzman R, Sauter N, Eriksen EF, et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May 2006. Crit Rev Oncol Hematol. 2007;62:148-152.